Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases


Results build on the data supporting the clinical profile...

Related Keywords

United States ,Canada ,France ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Netherlands ,Sweden ,Eliav Barr ,Walter Orenstein ,Emory University ,Linkedin ,Meeting Of The International Society Pneumonia ,Facebook ,Statement Of Merck Co Inc ,European Medicines Agency ,World Vaccine Congress West Coast ,Instagram ,Twitter ,Exchange Commission ,Merck Research Laboratories ,Merck Scientific Advisory Committee ,Us Centers For Disease ,European Society Of Clinical Microbiology ,Merck Co Inc ,Drug Administration ,Youtube ,European Society ,Clinical Microbiology ,Infectious Diseases ,International Society ,Pneumococcal Diseases ,Vaccine Congress West ,Scientific Advisory ,Merck Research ,Prescription Drug User Fee Act ,Disease Control ,Select Studies Presented ,Economic Burden ,Disease Studies ,Pneumococcal Vaccine Polyvalent ,Safety Information ,Pneumococcal Disease ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,